Revenio's iCare DRSplus included in FDA-cleared AI solution for diabetic retinopathy screening

Revenio's iCare DRSplus fundus imaging system is included in the first FDA-cleared AI-based diabetic retinopathy screening solution in the US, developed by iHealthScreen. The AI software enables automatic identification of patients needing further screening, targeting improved access and early detection in primary care settings.

This Wire brief sits within Fusion42's coverage of Medtech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.